MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$43,755K
Net Income
-$99,339K
Net Profit Margin
-227.03%
EPS
-$0.77
Unit: Thousand (K) dollars
Revenue Breakdown
    • Advanced Wound Care
    • Surgical And Sports Medicine
    • Grant
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
43,755
37,228
225,607
150,864
Cost of goods sold
23,673
25,772
73,641
36,251
Selling, general and administrative
53,965
65,186
100,174
79,743
Research and development
18,297
15,161
10,286
13,221
Write-down to fair value for asset held for sale
-
-
1,940
922
Fair value adjustment to assets held for sale
-1,188
-
-
-
Total operating expenses
94,747
106,119
186,041
130,137
Loss from operations
-50,992
-68,891
63,289
20,727
Interest income, net
-138
-380
-236
-415
Other income (expense), net
-26
38
-98
18
Total other income, net
112
418
138
433
Net loss before income taxes
-50,880
-68,473
63,427
21,160
Income tax benefit (expense)
45,387
-15,317
19,727
-407
Net loss and comprehensive loss
-96,267
-53,156
43,700
21,567
Accretion of redeemable convertible preferred stock to redemption value
170
159
150
140
Cumulative dividend on redeemable convertible preferred stock
2,902
2,844
2,788
2,734
Undistributed earnings allocated to participating redeemable convertible preferred stock
-
-
1,472
4,168
Net loss attributable to common stockholders, basic, total
-99,339
-56,159
39,290
14,525
Basic EPS
-0.77
-0.44
0.31
0.11
Diluted EPS
-0.77
-0.44
0.287
0.11
Basic Average Shares
128,674,548
127,797,013
126,921,657
126,881,709
Diluted Average Shares
128,674,548
127,797,013
136,995,475
130,848,995
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net lossattributable to common...-$99,339K (-714.12%↓ Y/Y)Net loss andcomprehensive loss-$96,267K (-924.99%↓ Y/Y)Cumulative dividend onredeemable convertible...$2,902K (8.24%↑ Y/Y)Accretion of redeemableconvertible preferred stock...$170K (31.78%↑ Y/Y)Interest income, net-$138K (79.37%↑ Y/Y)Advanced Wound Care$36,146K Surgical And SportsMedicine$6,659K Net loss beforeincome taxes-$50,880K (-329.95%↓ Y/Y)Income tax benefit(expense)$45,387K (1958.60%↑ Y/Y)Total other income,net$112K (-84.91%↓ Y/Y)Product$42,805K (-57.53%↓ Y/Y)Grant$950K (320.35%↑ Y/Y)Other income(expense), net-$26K (-135.62%↓ Y/Y)Loss from operations-$50,992K (-305.47%↓ Y/Y)Total revenue$43,755K (-56.68%↓ Y/Y)Total operatingexpenses$94,747K (-16.58%↓ Y/Y)Fair valueadjustment to assets held...-$1,188K Selling, general andadministrative$53,965K (-26.89%↓ Y/Y)Cost of goods sold$23,673K (-14.32%↓ Y/Y)Research and development$18,297K (76.02%↑ Y/Y)

Organogenesis Holdings Inc. (ORGO)

Organogenesis Holdings Inc. (ORGO)